Skip to main content

Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP.

Publication ,  Journal Article
Wong, HR; Cvijanovich, NZ; Anas, N; Allen, GL; Thomas, NJ; Bigham, MT; Weiss, SL; Fitzgerald, JC; Checchia, PA; Meyer, K; Quasney, M; Hall, M ...
Published in: Am J Respir Crit Care Med
August 15, 2017

RATIONALE: We previously derived and validated the Pediatric Sepsis Biomarker Risk Model (PERSEVERE) to estimate baseline mortality risk in children with septic shock. The PERSEVERE biomarkers are serum proteins selected from among the proteins directly related to 80 mortality risk assessment genes. The initial approach to selecting the PERSEVERE biomarkers left 68 genes unconsidered. OBJECTIVES: To determine if the 68 previously unconsidered genes can improve upon the performance of PERSEVERE and to provide biological information regarding the pathophysiology of septic shock. METHODS: We reduced the number of variables by determining the biological linkage of the 68 previously unconsidered genes. The genes identified through variable reduction were combined with the PERSEVERE-based mortality probability to derive a risk stratification model for 28-day mortality using classification and regression tree methodology (n = 307). The derived tree, PERSEVERE-XP, was then tested in a separate cohort (n = 77). MEASUREMENTS AND MAIN RESULTS: Variable reduction revealed a network consisting of 18 mortality risk assessment genes related to tumor protein 53 (TP53). In the derivation cohort, PERSEVERE-XP had an area under the receiver operating characteristic curve (AUC) of 0.90 (95% confidence interval, 0.85-0.95) for differentiating between survivors and nonsurvivors. In the test cohort, the AUC was 0.96 (95% confidence interval, 0.91-1.0). The AUC of PERSEVERE-XP was superior to that of PERSEVERE. CONCLUSIONS: PERSEVERE-XP combines protein and mRNA biomarkers to provide mortality risk stratification with possible clinical utility. PERSEVERE-XP significantly improves on PERSEVERE and suggests a role for TP53-related cellular division, repair, and metabolism in the pathophysiology of septic shock.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Respir Crit Care Med

DOI

EISSN

1535-4970

Publication Date

August 15, 2017

Volume

196

Issue

4

Start / End Page

494 / 501

Location

United States

Related Subject Headings

  • Shock, Septic
  • Risk Assessment
  • Respiratory System
  • Reproducibility of Results
  • ROC Curve
  • RNA, Messenger
  • Matrix Metalloproteinase 8
  • Male
  • Interleukin-8
  • Infant
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wong, H. R., Cvijanovich, N. Z., Anas, N., Allen, G. L., Thomas, N. J., Bigham, M. T., … Lindsell, C. J. (2017). Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP. Am J Respir Crit Care Med, 196(4), 494–501. https://doi.org/10.1164/rccm.201701-0066OC
Wong, Hector R., Natalie Z. Cvijanovich, Nick Anas, Geoffrey L. Allen, Neal J. Thomas, Michael T. Bigham, Scott L. Weiss, et al. “Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP.Am J Respir Crit Care Med 196, no. 4 (August 15, 2017): 494–501. https://doi.org/10.1164/rccm.201701-0066OC.
Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP. Am J Respir Crit Care Med. 2017 Aug 15;196(4):494–501.
Wong, Hector R., et al. “Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP.Am J Respir Crit Care Med, vol. 196, no. 4, Aug. 2017, pp. 494–501. Pubmed, doi:10.1164/rccm.201701-0066OC.
Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, Weiss SL, Fitzgerald JC, Checchia PA, Meyer K, Quasney M, Hall M, Gedeit R, Freishtat RJ, Nowak J, Raj SS, Gertz S, Grunwell JR, Lindsell CJ. Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP. Am J Respir Crit Care Med. 2017 Aug 15;196(4):494–501.

Published In

Am J Respir Crit Care Med

DOI

EISSN

1535-4970

Publication Date

August 15, 2017

Volume

196

Issue

4

Start / End Page

494 / 501

Location

United States

Related Subject Headings

  • Shock, Septic
  • Risk Assessment
  • Respiratory System
  • Reproducibility of Results
  • ROC Curve
  • RNA, Messenger
  • Matrix Metalloproteinase 8
  • Male
  • Interleukin-8
  • Infant